Biofinder wrote: First, let's consider the income from just the USA alone at 100% patient participation for plasminogen deficiency treatment with ProMetic's Ryplazim.
The prevalence of congenital plasminogen deficiency has been estimated at 1.6 per one million people. There are approximately 325 million people in the USA.
If my math is correct these should be the numbers:
325 million x 1.6 patients per/million = 520 plasminogen deficiency patients in USA.
520 patients in USA x $50,000 treatment cost per/year = $26 million per/year income.
$26 million in income from the USA, and that's at 100% patient participation...
Now let's consider INCOME FROM THE WORLD at 100% patient participation for plasminogen deficiency treatment with ProMetic's Ryplazim.
There are 7 billion people in the world.
If my math is correct these should be the numbers:
One billion is equal to a thousand millions (1,000 x 1,000,000).
7 billion = 7,000 million.
7,000 x 1.6 patients per/million = 11,200 plasminogen deficiency patients worldwide.
11,200 worldwide patients x $50,000 treatment cost per/year = 560 million per/year income.
So if ProMetic treats every single plasminogen deficiency patient in the world their yearly income would be 560 million.
If ProMetic treats 50% of the worldwide patients for plasminogen deficiency with Ryplazim, their yearly income would be 280 million.
If ProMetic treats 40% of the worldwide patients for plasminogen deficiency with Ryplazim, their yearly income would be 224 million.
If ProMetic treats 30% of the worldwide patients for plasminogen deficiency with Ryplazim, their yearly income would be 168 million.
If ProMetic treats 20% of the worldwide patients for plasminogen deficiency with Ryplazim, their yearly income would be 112 million.
If ProMetic treats 10% of the worldwide patients for plasminogen deficiency with Ryplazim, their yearly income would be 56 million.
Now all we have to do is kept waiting for the FDA to get off their collective asses and approve Ryplazim. tic tic tic